Butanvac (Coronavirus Vaccine) / Oswaldo Cruz Foundation, Butantan Institute 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  Butanvac (Coronavirus Vaccine) / Oswaldo Cruz Foundation, Butantan Institute
    Trial completion date, Trial primary completion date:  A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study. (clinicaltrials.gov) -  Dec 8, 2022   
    P1,  N=35, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Aug 2022 --> Feb 2023 Trial completion date: Jul 2023 --> Mar 2024 | Trial primary completion date: Jul 2023 --> Mar 2024
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand (clinicaltrials.gov) -  Nov 15, 2022   
    P1/2,  N=455, Completed, 
    Trial completion date: Jul 2023 --> Mar 2024 | Trial primary completion date: Jul 2023 --> Mar 2024 Recruiting --> Completed | Trial completion date: Dec 2023 --> Sep 2022 | Trial primary completion date: Dec 2023 --> Sep 2022
  • ||||||||||  Trial completion date, Trial primary completion date:  Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand (clinicaltrials.gov) -  Nov 14, 2022   
    P1/2,  N=460, Recruiting, 
    Recruiting --> Completed | Trial completion date: Dec 2023 --> Sep 2022 | Trial primary completion date: Dec 2023 --> Sep 2022 Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> Dec 2023
  • ||||||||||  Trial primary completion date:  Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand (clinicaltrials.gov) -  Aug 25, 2022   
    P1/2,  N=460, Recruiting, 
    Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> Dec 2023 Trial primary completion date: May 2022 --> May 2023
  • ||||||||||  Butanvac (Coronavirus Vaccine) / Oswaldo Cruz Foundation, Butantan Institute
    Preclinical, Journal:  Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. (Pubmed Central) -  Jul 2, 2022   
    Importantly, we show that the trivalent preparation, composed of the ancestral Wuhan, Beta, and Delta vaccines, substantially increases the levels of protection and of cross-neutralizing antibodies against mismatched, phylogenetically distant variants, including the currently circulating Omicron variant. We believe that these findings will help to guide efforts for pandemic preparedness against new variants in the future.
  • ||||||||||  Butanvac (Coronavirus Vaccine) / Oswaldo Cruz Foundation, Butantan Institute
    Enrollment closed, Phase classification, Enrollment change, Trial completion date, Trial primary completion date:  ADAPTCOV: Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil (clinicaltrials.gov) -  Jun 3, 2022   
    P1,  N=320, Active, not recruiting, 
    We believe that these findings will help to guide efforts for pandemic preparedness against new variants in the future. Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | N=5394 --> 320 | Trial completion date: Sep 2023 --> Nov 2022 | Trial primary completion date: Apr 2023 --> Dec 2021
  • ||||||||||  Butanvac (Coronavirus Vaccine) / Oswaldo Cruz Foundation, Butantan Institute
    @mab_sp125 @mellziland butanvac (Twitter) -  Jan 29, 2022   
  • ||||||||||  Enrollment open:  Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand (clinicaltrials.gov) -  Apr 1, 2021   
    P1/2,  N=460, Recruiting, 
    Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | N=5394 --> 320 | Trial completion date: Sep 2023 --> Nov 2022 | Trial primary completion date: Apr 2023 --> Dec 2021 Not yet recruiting --> Recruiting